Anti-PD-1/VEGF BsAb is under clinical development by 3SBio and currently in Phase II for Gynecological Cancer. According to GlobalData, Phase II drugs for Gynecological Cancer have a 27% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Anti-PD-1/VEGF BsAb’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Anti-PD-1/VEGF BsAb overview
The therapeutic candidate is under development for the treatment of advanced or metastatic solid tumors, non-mall cell lung cancer, metastatic colorectal cancer and gynecological tumors. It is being developed based on CLF2 BsAb platform targeting PD1 and VEGF.
3SBio overview
3SBio is a biotechnology company that discovers, develops, manufactures and markets biopharmaceutical products. The company develops recombinant or genetically engineered, protein-based products and other pharmaceutical product candidates to meet significant unmet medical needs in the areas of cancer and its supportive care, hematology, nephrology and dermatology among other disease conditions. The company distributes its products to hospitals, clinics and dialysis centers in China. The company sells its products in various countries including Thailand, Brazil, the Philippines and Pakistan among others. 3SBio is headquartered in Shenyang, Liaoning, China.
For a complete picture of Anti-PD-1/VEGF BsAb’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
